Bulimia Nervosa — Comprehensive Research Report

1. Disease Information

Overview. Bulimia nervosa (BN) is a psychiatric eating disorder characterized by recurrent episodes of binge eating (rapid consumption of an objectively large amount of food accompanied by a subjective sense of loss of control) followed by inappropriate compensatory behaviors intended to prevent weight gain — most commonly self-induced vomiting, but also laxative/diuretic/enema misuse, fasting, or excessive/compulsive exercise. Self-evaluation is disproportionately influenced by body shape and weight. Unlike anorexia nervosa, body weight in BN is typically within or above the normal range, which contributes to underrecognition (MRCPsych UK, ICD-11 criteria; StatPearls).

Key identifiers: - MONDO: MONDO:0005452 (bulimia nervosa) — confirmed via OLS/Monarch query (EBI OLS4 API, 2026-07-29 query) - OMIM: 607499 — "BULIMIA NERVOSA, SUSCEPTIBILITY TO; BULN" (a susceptibility locus entry, not a monogenic disorder) (OMIM:607499) - DOID: DOID:12129 - ICD-10-CM: F50.2 (Bulimia nervosa); ICD-11: 6B81 - ICD-11 diagnostic code: 6B81 - EFO: EFO_0005204 - HPO: HP:0100739 "Bulimia" (synonym: "Binge and purge") — confirmed via OLS4 API query - MeSH: D002032 (Bulimia Nervosa)

Synonyms: Bulimia, binge-purge syndrome, bulimarexia (historical, now discouraged).

Evidence base: Predominantly aggregated disease-level literature (case series, clinical cohorts, epidemiological registries, twin/family studies, GWAS meta-analyses, RCTs). Individual-patient EHR-level data exist but are less centralized than for BED/AN; national inpatient databases (e.g., US Nationwide Inpatient Sample) provide some individual-level aggregated statistics (PMC6034764).

Sources: ICD-11 Criteria (MRCPsych), StatPearls: Bulimia Nervosa, OMIM:607499

2. Etiology

Disease causal model: BN is multifactorial/polygenic — no single causal gene; risk arises from an interaction of genetic vulnerability (heritability ~50–60%), neurobiological reward/impulse-control dysregulation, and environmental/psychosocial exposures (sociocultural thin-ideal internalization, dieting, trauma).

Genetic risk factors

• Heritability: Twin studies estimate BN heritability at ~50–60% (one classic study: heritability of liability 55%; a subsequent twin study ~41%; proband-wise concordance 22.9% MZ vs. 8.7% DZ twins) (PubMed:1842216 — Kendler et al., "The genetic epidemiology of bulimia nervosa").
• Genetic correlation with anorexia nervosa: rg 0.46–0.79, indicating substantial shared genetic architecture between AN and BN (Nature Transl Psychiatry, 2023).
• GWAS: The Psychiatric Genomics Consortium – Eating Disorders (PGC-ED) is actively collecting BN samples; a 2025 GWAS of binge-eating behavior and anorexia nervosa found shared and unique genetic architecture across ED phenotypes (medRxiv 2025.01.31.25321397). A dedicated, well-powered BN-specific GWAS with genome-wide-significant loci has not yet been published (as of 2026), in contrast to AN (first genome-wide-significant locus reported in Watson et al. 2019, chr12).
• Candidate gene studies (largely underpowered/candidate-gene era, mixed replication):
• 5-HTTLPR (serotonin transporter promoter polymorphism, SLC6A4/hgnc:11050): implicated in reward processing, impulsivity, and eating-disorder susceptibility in meta-analyses; effects reported are inconsistent across studies.
• BDNF Val66Met (rs6265, hgnc:1033): studied primarily in AN; not robustly associated in BN-specific analyses.
• OPRD1 (delta-opioid receptor) and HTR1D: association signals reported with eating-disorder susceptibility (primarily AN datasets, with BN comorbid samples).
• ESR1/ESR2 (estrogen receptor genes): implicated given menstrual-cycle-linked binge-eating fluctuations.
• Note on evidence quality: Most single-candidate-gene associations in BN come from small case-control samples and have not been replicated in well-powered GWAS; treat as evidence_source: HUMAN_CLINICAL with low confidence pending GWAS confirmation.

Environmental / psychosocial risk factors

• Sociocultural pressure/thin-ideal internalization and dieting behavior are established proximal risk factors — strict caloric restriction predisposes to disinhibited binge eating (PMC2907970).
• Childhood sexual abuse and maltreatment: Childhood sexual abuse is a replicated non-specific risk factor for BN (elevated risk vs. no-ED controls, though not specific to BN vs. other psychiatric disorders) (PubMed, Am J Psychiatry 1992; ScienceDirect 1993).
• Adverse childhood experiences (ACEs): emotional, physical, and sexual abuse and emotional neglect show a dose-dependent relationship with eating-disorder symptom severity, including in BN (Frontiers 2022; PMC8860810).
• Perfectionism (particularly self-oriented perfectionism) and low self-esteem/body dissatisfaction are robust psychological risk factors.
• Sex: female sex is the strongest demographic risk factor (see §9).
• Family history of eating disorders, depression, substance use, or obesity.
• Weight stigma / weight-based teasing and participation in weight-class or appearance-focused activities (dance, gymnastics, modeling).

Protective factors

• Limited high-quality literature specifically on protective genetic variants. Environmentally, protective factors include: family meal structure/cohesion, media-literacy interventions, and body-acceptance-based prevention programs (see §13). No confirmed protective allele has reached genome-wide significance specifically for BN.

Gene-environment interaction

• The interaction of genetic loading (reward/impulsivity circuitry variants) with dieting/restriction as an environmental trigger is the dominant conceptual G×E model — caloric restriction unmasks binge-eating vulnerability in genetically susceptible individuals, consistent with rodent binge-eating-prone (BEP) vs binge-eating-resistant (BER) models responding differentially to identical intermittent palatable-food-access protocols (PMC3132131).

Sources: Kendler et al. PMID:1842216, Nature Transl Psychiatry 2023, PMC2907970, Frontiers 2022 ACEs

3. Phenotypes

Onset: Typically late adolescence to early adulthood (median onset ~18–21 years); can follow a period of dietary restriction or, less commonly, transition from anorexia nervosa (AN-restricting → BN crossover reported in a subset of AN patients) (PMC2275291).

Severity (DSM-5) is graded by weekly frequency of inappropriate compensatory behaviors: - Mild: 1–3 episodes/week - Moderate: 4–7 episodes/week - Severe: 8–13 episodes/week - Extreme: ≥14 episodes/week

Course: Episodic/fluctuating with a tendency toward chronicity if untreated; partial and full remission specifiers apply (see §8, §11).

Quality of life impact: Significant impairment in psychosocial functioning, social withdrawal (due to secrecy around bingeing/purging), impaired occupational/educational functioning, and elevated suicide risk associated with comorbid depression.

Sources: Cleveland Clinic J Med, StatPearls, ScienceDirect salivary gland, PMC2275291

4. Genetic / Molecular Information

• Causal genes: None establish a monogenic cause; BN is polygenic/multifactorial (OMIM 607499 is explicitly a "susceptibility" entry, not a Mendelian disease locus).
• Pathogenic variants: Not applicable in the classical Mendelian sense. No ClinVar pathogenic/likely-pathogenic variant classifications exist for BN as a discrete monogenic trait.
• Susceptibility loci / candidate genes (see §2 for detail): SLC6A4 (5-HTTLPR), BDNF (Val66Met/rs6265), OPRD1, HTR1D, ESR1/ESR2 — candidate-gene-era findings, generally not replicated at genome-wide significance.
• Polygenic architecture: Significant genetic correlation with anorexia nervosa (rg 0.46–0.79) and likely with major depression, anxiety disorders, OCD, and impulsivity/ADHD traits, consistent with the high psychiatric comorbidity burden (§9 below; Nature Transl Psychiatry 2023).
• Epigenetics: Limited direct BN-specific data; eating-disorder epigenetics literature (largely AN-focused) has examined DNA methylation changes in genes related to appetite regulation (e.g., POMC, AGRP) but BN-specific methylation studies are sparse and not yet conclusive.
• Chromosomal abnormalities: None established as causal for BN.
• Modifier genes: Not well characterized specifically for BN; impulsivity- and reward-related gene variants may modify symptom severity/course but data are preliminary.

Suggested gene terms if annotating candidate associations (low-confidence, candidate-gene-era evidence — flag accordingly): hgnc:11050 (SLC6A4), hgnc:1033 (BDNF), hgnc:8156 (OPRD1), hgnc:3444 (ESR1).

Sources: OMIM:607499, Nature Transl Psychiatry 2023, Frontiers 2024 AN polymorphisms

5. Environmental Information

• Sociocultural exposures: Media/thin-ideal internalization, social-media use (a Lebanese university-student study found problematic social media use associated with BN symptoms mediated by anxiety/depression — PMC10052263), weight stigma, appearance-focused athletic/artistic activities.
• Lifestyle factors: Chronic dieting/caloric restriction is the most consistently identified proximal behavioral trigger; alcohol/substance use frequently co-occurs and may share impulsivity-driven risk pathways.
• Life stress/trauma: Childhood abuse/neglect (§2), interpersonal stressors, and transitions (e.g., leaving home, athletic competition pressure).
• Infectious agents: Not applicable — BN has no known infectious etiology.

Sources: PMC10052263, NEDA Risk Factors

6. Mechanism / Pathophysiology

BN pathophysiology is best modeled as a reward-circuitry and homeostatic-appetite-signaling dysregulation cascade, upstream of the behavioral binge-purge cycle, with secondary systemic/metabolic consequences downstream of purging behaviors.

Causal chain (upstream → downstream)

1. Trigger: Caloric restriction/dieting (behavioral) and/or genetic predisposition (reward/impulsivity circuitry variants) →
2. Gut-hormone/appetite-signaling dysregulation: Impaired meal-induced ghrelin suppression, blunted postprandial cholecystokinin (CCK) rise, and lower postprandial leptin — collectively reducing satiety signaling and promoting continued/disinhibited intake (PMC3782835; ResearchGate ghrelin/leptin study) →
3. Mesolimbic reward-circuit hyperresponsivity: Altered dopamine D1/D2 receptor balance and interaction with serotonergic (mood/anxiety) systems in ventral striatum, orbitofrontal cortex; corticostriatal circuitry changes parallel those seen in substance-use disorders (ScienceDirect reward dysregulation; PMC3366171) →
4. Impaired top-down inhibitory control: Altered functional connectivity between dorsolateral prefrontal cortex (self-regulation) and striatum (reward), plus insular hyperactivity to food cues driving impulsive/compulsive food approach (PMC7311647 / Int J Neuropsychopharmacol 2020; Frontiers 2022 OFC) →
5. Binge-eating episode (loss-of-control overconsumption) →
6. Compensatory purging behavior (self-induced vomiting most common; laxative/diuretic misuse; excessive exercise), driven by shape/weight overvaluation and anxiety-reduction reinforcement (negative reinforcement loop: purging transiently reduces post-binge distress, reinforcing the cycle) →
7. Systemic/metabolic sequelae: Recurrent vomiting → gastric acid exposure to oral cavity/esophagus → dental enamel erosion (perimyolysis), esophagitis, rare Mallory-Weiss tears/Boerhaave esophageal rupture; hydrochloric acid and fluid loss → hypochloremic, hypokalemic metabolic alkalosis (pseudo-Bartter physiology via chronic volume depletion → secondary hyperaldosteronism) → risk of QTc prolongation and arrhythmia (torsades de pointes); salivary gland (parotid) hypertrophy with elevated serum amylase.

Gut-brain axis

Vagal gut-brain signaling governs mesolimbic dopamine dynamics; gut microbial metabolites (short-chain fatty acids, bile acids, tryptophan metabolites) and microbially synthesized neurotransmitters (dopamine, serotonin, GABA) may modulate reward-driven eating behavior, an emerging area of interest connecting the gut microbiome to BN's binge phenotype (PMC12857734; Bulimia Nervosa and Depression, gut microbiota).

Molecular pathways / GO term suggestions

• Serotonergic signaling: GO:0007210 serotonin receptor signaling pathway
• Dopaminergic reward signaling: GO:0007212 dopamine receptor signaling pathway
• Appetite regulation / satiety: GO:0032100 positive regulation of appetite; GO:0032099 negative regulation of appetite
• Response to nutrient levels / feeding behavior: GO:0007631 feeding behavior

Cell types / anatomical substrates (CL/UBERON suggestions)

• Neurons of ventral striatum/nucleus accumbens (reward): CL:0000540 neuron (generic; more specific CL terms for medium spiny neurons: CL:0000842? verify via OAK)
• Hypothalamic arcuate nucleus neurons (appetite regulation)
• Parotid gland acinar cells (secondary complication): UBERON:0001830 parotid gland

Biochemical abnormalities

Hypokalemia (HP:0002900), hypochloremia, metabolic alkalosis, hyperamylasemia (salivary isoenzyme predominance) — direct consequences of purging, not primary disease mechanism, but clinically critical downstream nodes.

Immune involvement

Not a primary feature; no established autoimmune/inflammatory mechanism in BN specifically (contrast with some appetite-neuropeptide-autoantibody findings reported in AN — PMC3782835 discusses "mixed" orexigenic/anorexigenic autoantibody signals relevant to both AN and BN, an area of ongoing investigation).

Model-system caveat

Much of the gut-hormone and reward-circuit mechanistic evidence blends human clinical (fMRI, hormone assay) studies with rodent binge-eating-prone (BEP) models; rodent bingeing models capture caloric/palatability-driven overconsumption and associated anxiety-like behavior but do not fully recapitulate purging behavior or the cognitive shape/weight-overvaluation component — a human-model mismatch worth flagging if curated as a HUMAN_MODEL_MISMATCH discussion.

Sources: PMC3782835, PMC12857734, ScienceDirect reward dysregulation, PMC7311647, Frontiers 2022 OFC VBM/FC, PMC6379643

7. Anatomical Structures Affected

Organ level (primary): Central nervous system (reward/limbic circuitry, hypothalamus) — primary driver; secondary/complication organs: gastrointestinal tract (oral cavity, esophagus, stomach), salivary glands (parotid), cardiovascular system (arrhythmia risk from electrolyte disturbance), renal system (electrolyte/fluid balance), endocrine/reproductive system (menstrual irregularity), dental/oral structures.

Body systems involved: Nervous (CNS reward/cognitive control), digestive (esophagus, salivary glands, dental enamel), cardiovascular, renal, endocrine/reproductive, psychiatric/behavioral.

UBERON suggestions: - UBERON:0001630 muscle organ / UBERON:0006562 — not directly relevant - UBERON:0001043 esophagus - UBERON:0001830 parotid gland - UBERON:0001723 tooth enamel (or UBERON:0001754 tooth) - UBERON:0002107 liver — not primary but monitored in refeeding/metabolic workups - UBERON:0002037 cerebellum / UBERON:0002420 basal ganglia (striatum) — reward circuitry - UBERON:0001876 amygdala

Tissue/cell level: Dental enamel (acid erosion), esophageal squamous epithelium (irritation/tears), parotid acinar tissue (hypertrophy), gastric mucosa.

Subcellular: Not a primary organelle-level disease; mitochondrial/oxidative changes are not established mechanistic features.

Lateralization: Not applicable (systemic/bilateral/symmetric where relevant, e.g., bilateral parotid enlargement).

Sources: Cleveland Clinic J Med, ScienceDirect salivary gland enlargement

8. Temporal Development

• Onset: Adolescence to early adulthood; median age of onset typically 18–21 years, though onset can occur earlier (early teens) or later. Onset pattern is typically insidious, often emerging after a period of dietary restriction (subacute/gradual).
• Progression: Variable — can remain stable, progress in severity/frequency, or fluctuate episodically; DSM-5 severity specifiers (mild/moderate/severe/extreme) are frequency-based, not stage-based.
• Disease course pattern: Predominantly episodic/relapsing-remitting; approximately two-thirds of patients achieve substantial improvement or recovery long-term, with frequent relapses in between, and 15–20% follow a chronic protracted course (Am J Psychiatry, "Outcome of bulimia nervosa" 2009; PubMed:19884225).
• Remission patterns: Both spontaneous and treatment-induced remission occur; risk of relapse declines notably after ~4 years post-presentation. Full and partial remission are formal DSM-5 specifiers.
• Critical periods: Adolescence/young adulthood represents the key vulnerability window (developmental identity formation + peak dieting-behavior prevalence); early intervention within the first few years of illness onset is associated with better prognosis.

Sources: PubMed:9054777, PubMed:19884225, PubMed:9892257

9. Inheritance and Population

Epidemiology

• Lifetime prevalence: 0.8–2.6% among women; 0.1–0.2% among men (some sources cite up to 3% of females and >1% of males) (search synthesis of multiple epidemiological reviews).
• Global burden trend: Age-standardized prevalence increased ~43% globally from 1990–2021 (EAPC 0.57); burden correlates positively with socioeconomic development; Australia had the highest burden in 2021; fastest growth in East and South Asia; decline in high-income North America (PMC12164058; J Eating Disorders 2025).
• Age distribution: Most common in adolescents (10–19y) and young adults (20–40y), especially in Western/high-income countries.

Inheritance pattern

Multifactorial/polygenic — not Mendelian. OMIM designates a "susceptibility" locus construct (607499), consistent with complex trait architecture. - Heritability: ~50–60% (twin studies). - Penetrance/expressivity: Not applicable in the Mendelian sense; risk is probabilistic/polygenic, modulated heavily by environmental exposure (dieting, trauma). - Genetic anticipation, germline mosaicism, founder effects, consanguinity, carrier frequency: Not applicable to this polygenic behavioral/psychiatric disorder.

Population demographics

• Sex ratio: Strongly female-predominant (historically cited ~10:1 female:male in clinical samples, though population-based estimates suggest a narrower gap and rising recognition in males).
• Geographic distribution: Higher burden in higher-SES/Western countries historically; rapidly rising in East/South Asia; regional variation reflects both true prevalence differences and detection/reporting differences.

Sources: PMC8500372, PMC12164058, Oxford Academic Eur J Public Health 2026

10. Diagnostics

Clinical/laboratory tests

• Electrolytes: Serum potassium, chloride, bicarbonate — screen for hypokalemic, hypochloremic metabolic alkalosis (most common abnormality, ~27.4% of BN patients show metabolic alkalosis; hypochloremia ~23.8%; hypokalemia ~13.7%) (search synthesis of medical-complications literature).
• Serum amylase: Elevated (salivary isoenzyme) correlating with binge/purge frequency and parotid enlargement — useful non-invasive marker of active purging (ScienceDirect).
• ECG: To assess QTc interval, especially with significant hypokalemia — risk of torsades de pointes.
• Dental exam: Perimyolysis (lingual-surface enamel erosion of maxillary teeth) is a sensitive clinical sign of chronic self-induced vomiting (PMC11986531 dentin hypersensitivity study).
• Imaging: Not routinely required for diagnosis; used if complications suspected (e.g., chest/abdominal imaging for suspected esophageal rupture).

Genetic testing

Not clinically indicated — BN is not a Mendelian/single-gene disorder; no diagnostic genetic test exists.

Screening tools

• SCOFF questionnaire: 5-item screen (Sick, Control, One stone, Fat, Food); cutoff ≥2 "yes" answers; sensitivity 84.6%, specificity 89.6% in primary care, detecting all AN and BN cases and 77% of EDNOS in the validating study (search synthesis).
• EDE-Q (Eating Disorder Examination Questionnaire): 28-item self-report across 4 subscales (restraint, eating concern, shape concern, weight concern); optimal global-score cutoff ≥2.80 (sensitivity/specificity ~0.80/0.80) (ScienceDirect EDE-Q vs SCOFF).

Clinical diagnostic criteria

• DSM-5: Recurrent binge eating + recurrent inappropriate compensatory behavior, both occurring on average ≥1×/week for 3 months; self-evaluation unduly influenced by shape/weight; not occurring exclusively during AN episodes.
• ICD-11 (6B81): Similar core criteria; frequency threshold ≥1×/week for ≥1 month; notably includes "subjective binges" (loss of control even without objectively large intake) — a key ICD-11/DSM-5 divergence. About 98% diagnostic concordance between ICD-11 and DSM-5 in inpatient samples (PMC6515596).
• Differential diagnosis: Anorexia nervosa binge-purge subtype (distinguished by significantly low body weight), binge-eating disorder (no regular compensatory behavior), Kleine-Levin syndrome, atypical depression with hyperphagia, Prader-Willi syndrome (in relevant developmental contexts), medical causes of vomiting.

Sources: SCOFF validation, ICD-11 field study PMC6515596, PMC11986531

11. Outcome/Prognosis

• Mortality: Crude mortality rate ~0.3% across pooled follow-up studies (7 deaths/2,194 subjects, likely an underestimate given short follow-up); more recent cohort analyses indicate a ~50% increased risk of death (all-cause) relative to general population (PubMed:23771148 — longitudinal mortality study).
• Long-term recovery: At 5–10 years, ~50% fully recover; ~20% continue to meet full BN criteria; ~30% relapse into bulimic symptoms after initial improvement (risk of relapse declines after ~4 years) (PubMed:9054777).
• Quarter-century synthesis: ~45% full recovery on average, ~27% considerable improvement, ~23% chronic protracted course (Am J Psychiatry 2009).
• Prognostic factors: Impulsivity (personality trait) associated with poorer outcome; comorbid depression/substance use predicts persistence (ScienceDirect comorbid depression/substance use); treatment speeds recovery but doesn't strongly alter outcome beyond 5 years post-presentation.
• Complications driving morbidity: Electrolyte-disturbance-related cardiac arrhythmia, GI complications (Mallory-Weiss tear, rare Boerhaave esophageal rupture), dental damage, and psychiatric comorbidity burden (depression, anxiety, substance use) are the principal drivers of long-term morbidity.
• QoL: Chronic BN is associated with substantial reduction in psychosocial functioning and quality of life, improving with successful treatment.

Sources: PubMed:23771148, PubMed:9054777, Am J Psychiatry 2009

12. Treatment

Pharmacotherapy

• Fluoxetine (SSRI; CHEBI:5118): The only FDA-approved medication for BN, at a higher dose (60 mg/day) than typical antidepressant dosing. RCT evidence: fluoxetine reduces core binge/purge symptoms and psychological features in the short term (PubMed:9299800; systematic review PubMed:17370288).
• Combination fluoxetine + CBT: All three arms (fluoxetine alone, CBT alone, combination) showed improvement in an RCT; combination was superior to medication alone on some parameters but not significantly superior to CBT alone (PubMed:9299800).
• Topiramate (anticonvulsant, off-label): Reduces binge urges via effects on appetite/impulse-control-relevant neurotransmission; studied in partial responders (NCT00988481).
• Lisdexamfetamine (psychostimulant, FDA-approved for BED, off-label in BN): Emerging open-label feasibility data in BN adults show reductions in binge/purge frequency (PMC10204259); case-series data on psychostimulants generally show reduced binge/purge days (PubMed:28111772).

Psychotherapy (first-line)

• Cognitive Behavioral Therapy (CBT), including enhanced CBT (CBT-E): Leading evidence-based treatment; reduces core behavioral/psychological features in short and long term (systematic review PubMed:17370288). MAXO suggestion: cognitive behavioral therapy — closest MAXO/NCIT term should be verified via OAK (NCIT:C49236 Therapeutic Procedure as a fallback if no specific CBT term exists).
• Interpersonal psychotherapy (IPT): An evidence-based alternative, slower onset of effect but comparable longer-term outcomes to CBT in some trials.
• Guided self-help CBT models have been piloted in non-Western settings (e.g., Japan) with promising feasibility (PMC5918895; PMC7041176).

Nutritional/behavioral/supportive

• Nutritional counseling/rehabilitation, regular meal-pattern restoration, and psychoeducation are standard adjunctive components.
• Group therapy formats are under active study (e.g., "Step by Step Group Therapy for Bulimia Nervosa" — NCT06063278).
• Physical exercise and dietary therapy have been compared to CBT in RCT protocols (PED-t trial — PMC5427572).

Medical/supportive management of complications

Electrolyte repletion (aggressive potassium correction to prevent arrhythmia), dental care, and monitoring for esophageal injury in severe purging.

Experimental / advanced therapeutics

No gene therapy, cell therapy, or immunotherapy approaches are applicable — BN is a behavioral/psychiatric disorder, not amenable to these modalities. Active clinical trial areas include neurobiological/fMRI-guided treatment-response studies (e.g., "Neurobiology of Bulimia Nervosa" — NCT04225221) and self-control/impulsivity-targeted interventions (NCT04409457).

Treatment algorithm

Guideline-concordant stepped care: CBT-E (or IPT) as first-line psychotherapy; fluoxetine as first-line/adjunctive pharmacotherapy or for partial responders; topiramate/psychostimulants as off-label augmentation in treatment-resistant cases; inpatient/higher level of care for medical instability (severe electrolyte disturbance, cardiac risk).

Suggested MAXO terms: MAXO:0000950 supportive care (nutritional/medical monitoring), pharmacotherapy generically under NCIT:C15986, with therapeutic_agent CHEBI binding to fluoxetine (CHEBI:5118) and topiramate; psychotherapy modality would need a dedicated MAXO/NCIT lookup (verify via OAK — likely closest is a general "psychotherapy" or "behavioral therapy" NCIT term).

Sources: PubMed:9299800, PubMed:17370288, PMC10204259, PubMed:28111772

13. Prevention

• Primary prevention: School- and media-literacy-based programs targeting thin-ideal internalization, body dissatisfaction, and dieting behavior; universal and targeted (high-risk) prevention curricula have shown modest efficacy in reducing eating-disorder risk-factor endorsement.
• Secondary prevention/early detection: Primary-care screening with SCOFF or EDE-Q in at-risk populations (adolescent girls, athletes in weight-sensitive sports, individuals with early dieting behavior or subthreshold binge/purge symptoms).
• Tertiary prevention: Relapse-prevention components within CBT-E; ongoing monitoring of electrolytes/dental health in patients with residual purging behavior to prevent life-threatening complications (arrhythmia, esophageal rupture).
• Behavioral interventions: Reducing dieting behavior, promoting normalized eating patterns, media-literacy and body-acceptance interventions.
• Counseling: Family-based approaches and psychoeducation for caregivers; no genetic counseling role given the polygenic, non-Mendelian architecture.
• Public health: Broader social-media/advertising regulation discussions around thin-ideal content; weight-stigma reduction campaigns.
• Immunization/prophylaxis: Not applicable.

Sources: General synthesis from NEDA risk factors and prevention literature cited in etiology searches above.

14. Other Species / Natural Disease

BN as clinically defined (with its cognitive component of shape/weight overvaluation) is a human-specific psychiatric construct; there is no known naturally occurring veterinary analog in companion animals or wildlife, and no OMIA entry exists for a bulimia-like natural disease. This is distinct from binge-eating/palatability-driven overconsumption, which is modeled experimentally (see §15).

• Taxonomy: Not applicable for natural disease.
• Zoonotic potential: Not applicable.

15. Model Organisms

BN pathophysiology (specifically the binge-eating component) is modeled almost exclusively via induced rodent models, since no genetic/knockout model recapitulates the full human syndrome (including purging and cognitive shape/weight overvaluation).

• Binge-Eating-Prone (BEP) / Binge-Eating-Resistant (BER) rat model: Rats undergo repeated intermittent exposure to palatable food; individual variation in over- vs under-consumption identifies BEP vs. BER phenotypes, used to study neurobiological risk factors for binge eating (Springer protocol).
• Sugar-bingeing / intermittent access model: Periodic (e.g., 12-hour) food restriction followed by scheduled access to 25% glucose or 10% sucrose solution; over ~3 weeks produces a bingeing pattern (up to 32% of caloric intake from sugar), used as a model of behavioral/neurochemical "sugar addiction" relevant to binge-type eating disorders (PMC4361030).
• Neurochemical findings from these models: Altered dopamine D1/D2 receptor balance, changes in midbrain serotonin neurotransmission — mirroring hypothesized human corticostriatal reward dysregulation (ScienceDirect; PMC3366171).
• Behavioral readouts: Elevated Plus-Maze anxiety-like behavior is increased (small effect size) across pooled rodent binge-eating studies (systematic review/meta-analysis of 18 studies) (ScienceDirect meta-analysis).
• Model limitations: Rodent bingeing models do not capture compensatory purging behavior, body-image/shape-weight cognitive overvaluation, or the menstrual-cycle/estrogen-linked symptom fluctuation seen in humans — an important human-model-mismatch caveat for any hypothesis-flagged pathophysiology node built from these data.
• Applications: Used to dissect neurochemical/circuit-level contributions to loss-of-control eating, palatability-driven reward, and pharmacological screening (e.g., topiramate, opioid-antagonist, and serotonergic-agent testing) relevant to BN's binge component.

Sources: PMC3132131, Springer BEP/BER protocol, PMC4361030, MDPI 2023 rodent pharmacotherapy review

Summary of Key Ontology Term Suggestions

Notes on Evidence Gaps for Curation

1. No BN-specific genome-wide-significant GWAS locus has been published as of this report (contrast with AN); candidate-gene findings (5-HTTLPR, BDNF, OPRD1, ESR1) should be curated as evidence_source: HUMAN_CLINICAL with an explicit caveat about small-sample/candidate-gene-era limitations, or considered for a KNOWLEDGE_GAP discussion entry.
2. No dedicated HP terms exist for several clinically important signs (Russell's sign, perimyolysis/dental erosion, parotid enlargement specifically) — these will need either a best-fit broader HP term or documentation via notes/free text rather than a forced ontology binding.
3. Rodent binge-eating models do not recapitulate purging or cognitive shape/weight overvaluation — a strong candidate for a HUMAN_MODEL_MISMATCH discussion node if a MODEL_ORGANISM-sourced pathophysiology claim (e.g., dopamine D1/D2 imbalance) is included.
4. All PMIDs/URLs above should be independently re-verified against cached abstracts (just fetch-reference) and exact-quote snippets extracted before use in KB YAML, per dismech's evidence SOP — this report is a research lead document, not pre-validated curation content.

Sources (consolidated): - ICD-11 Criteria for Bulimia Nervosa (MRCPsych UK) - ICD-11 field study, PMC6515596 - StatPearls: Bulimia Nervosa - OMIM:607499 - Kendler et al., PMID:1842216 - Nature Translational Psychiatry 2023 - PMC2907970 — Bulimia nervosa review - Frontiers 2022 — ACEs and eating disorders - PMC8860810 — childhood maltreatment network analysis - PMC3782835 — orexigenic/anorexigenic autoantibodies - PMC12857734 — gut-brain vagal axis and dopamine - ScienceDirect — reward system dysregulation animal models - PMC3366171 - PMC7311647 / Int J Neuropsychopharmacol 2020 - Frontiers 2022 — OFC VBM/FC study - PMC6379643 — resting-state fMRI BED/BN - Cleveland Clinic Journal of Medicine — medical complications - ScienceDirect — salivary gland enlargement/amylase - PMC4392812 — medical complications review - PMC11986531 — dentin hypersensitivity in BN - PMC6034764 — hospitalization outcomes/comorbidities - PubMed:9299800 — fluoxetine + CBT RCT - PubMed:17370288 — treatment systematic review - PMC10204259 — lisdexamfetamine feasibility trial - PubMed:28111772 — psychostimulants case reports - NCT00988481 — topiramate augmentation - NCT06063278 — group therapy - NCT04225221 — neurobiology of BN - PubMed:23771148 — longitudinal mortality study - PubMed:9054777 — outcome in bulimia nervosa - Am J Psychiatry 2009 — quarter-century outcome review - PMC8500372 — incidence/prevalence/mortality review - PMC12164058 — GBD 2021 analysis - PMC2275291 — AN-restricting to BN transition - PMC3132131 — rat models of binge eating - PMC4361030 — sugar addiction rat model - Springer protocol — BEP/BER model - PubMed:18359005 — EDE-Q vs SCOFF screening

Bulimia Nervosa: Disease Characteristics Research Report

Executive summary

Bulimia nervosa (BN) is a psychiatric eating disorder defined by recurrent, objectively large binge-eating episodes with loss of control, recurrent inappropriate compensatory behavior, and excessive influence of weight or shape on self-evaluation. Under DSM-5-style criteria, binge eating and compensation occur at least weekly for 3 months and do not occur exclusively during anorexia nervosa. BN is usually episodic or relapsing, often begins in adolescence, and can occur at any body mass index; consequently, visual recognition is unreliable. Current understanding is that BN is multifactorial and polygenic rather than a single-gene disorder. Psychological vulnerability, sociocultural pressures, trauma, dieting, and altered reward/inhibitory-control circuitry interact to produce and perpetuate binge–purge cycles. (yu2023efficacyofpharmacotherapies pages 1-2, wilson2024bulimianervosaand pages 1-2, donnelly2018neuroimaginginbulimia pages 1-2, barakat2023riskfactorsfor pages 7-8)

The strongest evidence-based treatment for adults is eating-disorder-focused cognitive behavioral therapy, commonly CBT-E. Family-based treatment is particularly important for adolescents. Fluoxetine is the best-established medication and is generally adjunctive rather than a replacement for psychotherapy. Medical monitoring is essential because vomiting, laxative or diuretic misuse, fasting, and excessive exercise may produce electrolyte, cardiac, gastrointestinal, dental, and endocrine complications. (yu2023efficacyofpharmacotherapies pages 1-2, gkintoni2024clinicalinterventionstrategies pages 30-31, alharbi2024effectivetreatmentapproaches pages 5-6)

1. Disease information

Definition and identifiers

• Preferred name: Bulimia nervosa.
• Abbreviation/synonym: BN; historically “bulimia.” “Binge–purge eating disorder” is descriptive but is not the preferred controlled label.
• Category: Feeding or eating disorder; psychiatric disease.
• MONDO: MONDO:0005452, confirmed by the Open Targets disease record. No associated molecular targets were returned, consistent with the absence of a validated single causal target. (OpenTargets Search: bulimia nervosa)
• ICD-10-CM: F50.2, bulimia nervosa.
• ICD-11: 6B81, bulimia nervosa.
• MeSH: Bulimia Nervosa.
• OMIM/Orphanet: No appropriate Mendelian OMIM phenotype or rare-disease Orphanet entry is established for ordinary BN; assigning one would incorrectly imply monogenic or rare-disease causation.

These are aggregated disease-level definitions. They are not individual-patient EHR observations, although ICD/SNOMED labels can be instantiated in EHRs.

Diagnostic concept

A binge includes unusually large food consumption in a discrete interval and subjective loss of control. Compensation can include self-induced vomiting, laxative or diuretic misuse, fasting, or excessive exercise. Weight/shape overvaluation is required, and BN is differentiated from binge-eating disorder by recurrent compensation and from anorexia nervosa binge–purge type by the absence of persistently significantly low weight meeting AN criteria. (yu2023efficacyofpharmacotherapies pages 1-2, wilson2024bulimianervosaand pages 1-2, wilson2024bulimianervosaand pages 2-3)

2. Etiology

Causal and risk factors

BN has no single sufficient cause. Evidence supports interacting genetic susceptibility, developmental and psychiatric vulnerability, environmental exposure, and learned behavioral reinforcement. A 2023 rapid review grouped eating-disorder risks into genetics; microbiota/autoimmune factors; childhood exposures; personality and psychiatric comorbidity; sex/gender; socioeconomic and minority-related factors; body image/social influence; and elite sport. It emphasized that association does not necessarily establish causality. (barakat2023riskfactorsfor pages 7-8)

Genetic susceptibility. Family/twin literature supports moderate heritability, but the retrieved evidence does not justify a precise BN-specific estimate. Candidate associations have been reported in dopamine- and serotonin-related neuroendocrine receptors, glucocorticoid-pathway genes, and the serotonin-transporter-linked polymorphic region, 5-HTTLPR. These are susceptibility findings—not ACMG-pathogenic variants—and are not suitable for clinical prediction. Binge-type eating disorders show genetic overlap with ADHD, while BN also shares genomic liability with overweight/obesity. (barakat2023riskfactorsfor pages 7-8)

Environmental/developmental risks. Childhood maltreatment or trauma, body dissatisfaction, internalization of thin/appearance ideals, appearance-focused social media, dieting or restraint, weight stigma, mood/anxiety symptoms, impulsivity, and family/social stress are associated risks. Autoimmune or autoinflammatory disease in childhood was associated with a reported 73% increase in BN risk, although confounding and mechanisms remain uncertain. (butler2021theroleof pages 10-12, barakat2023riskfactorsfor pages 7-8)

Gene–environment interaction. Reported examples include maltreatment interacting with glucocorticoid-receptor pathway polymorphisms or 5-HTTLPR. Lower cortisol following maltreatment has been reported in BN relative to controls, suggesting stress-axis calibration may mediate vulnerability. These findings remain observational and are not actionable biomarkers. (barakat2023riskfactorsfor pages 7-8)

Protective factors

No reproducible protective allele is established. Plausible environmental protection includes positive body image, reduced appearance-based social comparison, media literacy, supportive family/peer relationships, flexible eating, avoidance of restrictive dieting, early recognition, and rapid access to evidence-based care. These should be treated as prevention targets rather than proven disease-specific protective mechanisms.

3. Phenotypes

Core behavioral and psychiatric phenotypes

• Recurrent binge eating with loss of control—episodic and variable in frequency.
• Self-induced vomiting or other compensation: laxatives/diuretics, fasting, or driven exercise.
• Overvaluation of body weight/shape, body dissatisfaction, dietary restraint, shame, secrecy, and impaired emotion regulation.
• Depression, anxiety, self-harm, suicidality, and substance-use symptoms are important comorbid phenotypes. Review estimates include mood disorders in 43%, anxiety disorders in 53%, and lifetime mood disorder in 80–90%, but estimates vary substantially by sample and definition. (yu2023efficacyofpharmacotherapies pages 1-2, donnelly2018neuroimaginginbulimia pages 1-2)

Physical signs, manifestations, and laboratory abnormalities

Vomiting may cause dental enamel erosion, caries, pharyngeal trauma, salivary-gland enlargement, reflux or other gastrointestinal symptoms, dehydration, and electrolyte/acid–base abnormalities. Severe electrolyte disturbance can precipitate weakness, syncope, QT abnormalities, or arrhythmia. Menstrual irregularity can occur, although it is less diagnostically central than in restrictive disorders. Normal or high weight does not exclude serious medical instability. (wilson2024bulimianervosaand pages 1-2, wilson2024bulimianervosaand pages 2-3, alharbi2024effectivetreatmentapproaches pages 5-6)

Suggested HPO mappings include Binge eating, Self-induced vomiting, Abnormality of electrolyte homeostasis, Hypokalemia, Dehydration, Cardiac arrhythmia, Dental erosion, Salivary-gland enlargement, Menstrual irregularity, Anxiety, and Depressive symptom. Exact term IDs should be validated against the current HPO release before ingestion.

Severity, progression, and quality of life

DSM severity is based on weekly compensatory-event frequency: mild 1–3, moderate 4–7, severe 8–13, and extreme ≥14, with clinical judgment allowing adjustment for disability. Course is commonly fluctuating or relapsing. Individual phenotypes impair school/work attendance, relationships, finances, concentration, self-esteem, and social eating. The evidence base uses inconsistent remission and recovery definitions, limiting precise cross-study estimates.

4. Genetic and molecular information

BN should be annotated as multifactorial/polygenic, not Mendelian. There are no established causal genes, pathogenic germline variants, recurrent chromosomal abnormalities, founder mutations, carrier frequencies, penetrance estimates, anticipation, or germline mosaicism relevant to routine BN. Correspondingly, Open Targets returned zero disease–target associations for MONDO:0005452. (OpenTargets Search: bulimia nervosa)

Reported candidate loci in serotonergic, dopaminergic, and glucocorticoid signaling are association-level observations. They should not be labeled pathogenic or likely pathogenic under ACMG/AMP criteria. No validated modifier gene or clinically useful pharmacogenomic marker exists for selecting CBT or fluoxetine specifically in BN. (barakat2023riskfactorsfor pages 7-8)

Epigenetic evidence specific to BN is sparse and confounded by trauma, diet, medication, smoking, adiposity, and illness state. No methylation signature is validated diagnostically. WGS, WES, gene panels, CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are therefore not indicated for uncomplicated BN; they are reserved for syndromic presentations suggesting another disorder.

5. Environmental information

There is no infectious cause and no evidence supporting vaccination, antimicrobial treatment, or zoonotic control. No toxin, radiation, or occupational exposure is established as a specific cause. Relevant exposures are predominantly psychosocial and behavioral: restrictive dieting, weight cycling, appearance pressure, social-media comparison, bullying/weight stigma, trauma, elite sports emphasizing leanness, and family or peer reinforcement. Alcohol, nicotine, stimulant, or other substance use may coexist and can increase medical and behavioral risk. (barakat2023riskfactorsfor pages 7-8)

6. Mechanism and pathophysiology

Integrated causal model

A defensible causal chain is: polygenic/developmental vulnerability plus appearance, trauma, or dieting exposures → negative affect, restraint, altered interoception and reward valuation → food restriction and heightened cue salience → loss-of-control binge → acute distress and fear of weight gain → purging/fasting/exercise, which provides short-term negative reinforcement → renewed restriction and repeated cycles. Recurrent purging then produces downstream electrolyte, dental, salivary, gastrointestinal, and cardiovascular injury.

Neural circuitry and signaling

Human neuroimaging studies report reduced activity in frontostriatal control circuits and abnormal responses in the insula, amygdala, middle frontal gyrus, orbitofrontal cortex, and anterior cingulate cortex. These findings support impaired inhibitory control, altered reward sensitivity, food-cue attentional bias, and emotion/interoceptive dysregulation. Greater binge/bulimic frequency correlates with more pronounced neural alteration. However, a systematic review found substantial methodological heterogeneity and small samples, so no imaging pattern is diagnostic or demonstrably causal. (donnelly2018neuroimaginginbulimia pages 1-2)

Suggested processes include GO concepts related to regulation of feeding behavior, dopamine receptor signaling, serotonin receptor signaling, response to stress, reward learning, and behavioral response inhibition. Relevant cells include excitatory and inhibitory neurons, dopaminergic neurons, serotonergic neurons, and peripheral T lymphocytes; current evidence does not support a BN-specific cellular lesion.

Gut–brain, metabolic, and immune findings

Microbiome/metabolite differences have been reported across eating disorders and binge–purge versus restricting patterns, but small, mixed-diagnosis samples and diet/adiposity confounding prevent a BN-specific signature. These findings are hypothesis-generating, not grounds for probiotics or fecal transplantation as standard treatment.

BN does not show a consistent systemic inflammatory-cytokine phenotype: meta-analysis found no reliable IL-6 or TNF-α difference; PBMC production of IFN-γ, IL-1β, IL-6, and TNF-α was also not consistently altered. A cohort of 76 obese BN patients showed higher IL-1β, IL-6, and TNF-α, plausibly attributable to adiposity. Lower CD4/CD8 ratios and reduced CD2, CD3, CD4, CD8, and CD57 have been reported, but confounding and replication limitations preclude an immune biomarker. (butler2021theroleof pages 10-12)

No validated transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, CRISPR-screen, or multi-omic diagnostic signature exists for BN.

7. Anatomical structures affected

The primary functional system is the central nervous system, especially frontostriatal, salience, reward, and emotion-regulation networks. Secondary injury involves teeth/enamel, oral mucosa and pharynx, salivary glands, esophagus and gastrointestinal tract, kidneys through volume/electrolyte disturbance, heart through electrolyte-mediated conduction abnormalities, and reproductive/endocrine systems. (wilson2024bulimianervosaand pages 1-2, donnelly2018neuroimaginginbulimia pages 1-2, alharbi2024effectivetreatmentapproaches pages 5-6)

Suggested UBERON annotations are brain, cerebral cortex, insula, amygdala, orbitofrontal cortex, anterior cingulate cortex, striatum, tooth enamel, salivary gland, pharynx, esophagus, stomach, kidney, and heart. Lateralization is not a defining feature. Subcellular pathology is not established; synaptic and receptor signaling are implicated functionally rather than through a known organelle defect.

8. Temporal development

Onset is typically adolescent to young-adult and often insidious, beginning with dieting, shape concern, or episodic bingeing. One review reported average onset at 16–17 years, whereas a 2024 disparities review cited median onset at 12.4 years; the discrepancy reflects different samples and ascertainment and should not be collapsed into one value. (yu2023efficacyofpharmacotherapies pages 1-2, wilson2024bulimianervosaand pages 1-2)

The disease is episodic or relapsing-remitting and can become chronic. Diagnostic crossover with anorexia nervosa or other specified eating disorders occurs. Early treatment is a key opportunity because repeated cycles become behaviorally reinforced and medical complications accumulate. Remission may be spontaneous or treatment-induced, but relapse prevention and follow-up remain necessary.

9. Inheritance and population

Lifetime prevalence estimates vary by diagnostic threshold and survey. Recent reviews cite approximately 0.9–3% overall, 1.5–3% in females, and 0.5% to >1% in males; 12-month prevalence around 0.4% has been reported. These values should be represented as ranges rather than a universal estimate. (yu2023efficacyofpharmacotherapies pages 1-2, wilson2024bulimianervosaand pages 1-2)

Females are diagnosed more often, but BN occurs in males, gender-diverse people, all racial/ethnic groups, and across body sizes and socioeconomic strata. Research samples have often been 80–100% female and 80–100% White, meaning apparent demographic gradients partly reflect ascertainment and access bias. Older adults, males, and racial minorities remain underrepresented. (wilson2024bulimianervosaand pages 1-2, wilson2024bulimianervosaand pages 2-3)

Inheritance is polygenic/multifactorial with incomplete, probabilistic expression. Mendelian penetrance, carrier frequency, consanguinity, anticipation, founder effects, and geographic variant distributions are not applicable.

10. Diagnostics

Clinical assessment

Diagnosis is made by confidential clinical interview using DSM-5-TR or ICD-11 criteria. Assessment should characterize objective and subjective binges, loss of control, each compensatory method, weekly frequency/duration, shape/weight overvaluation, dietary restraint, exercise, medications/substances, menstrual history, self-harm/suicide risk, and comorbidity. Collateral family information is useful in adolescents.

Screening instruments such as SCOFF can identify possible eating disorders but cannot establish BN. There is no newborn, carrier, prenatal, genomic, or population laboratory screen.

Medical evaluation

Physical assessment should include weight trajectory rather than BMI alone, pulse, blood pressure including orthostasis, temperature, hydration, oral/dental and salivary examination, and signs of self-induced vomiting. Depending on severity and purging method, tests commonly include CBC, electrolytes, bicarbonate, renal function, glucose, magnesium, phosphate, liver tests, urinalysis, pregnancy testing when relevant, and ECG. Electrolyte abnormality, dehydration, and arrhythmia are indications for urgent escalation or hospitalization. (alharbi2024effectivetreatmentapproaches pages 5-6)

No blood, imaging, electrophysiological, biopsy, genetic, or omics biomarker confirms BN. MRI/PET/fMRI are research tools, not diagnostic tests. (donnelly2018neuroimaginginbulimia pages 1-2)

Differential diagnosis

Important alternatives include binge-eating disorder, anorexia nervosa binge–purge type, purging disorder/OSFED, avoidant-restrictive food intake disorder, mood or bipolar illness with appetite change, substance-induced behavior, gastrointestinal disease, endocrine disease, and neurologic conditions. The decisive distinctions are low-weight AN status, presence/absence of recurrent compensation, objective binge criteria, and weight/shape psychopathology.

11. Outcome and prognosis

Recovery is possible, including after prolonged illness. One narrative review cited remission approaching 80% with proper treatment, but this should be interpreted cautiously because outcome definitions and follow-up periods vary. CBT effects are generally moderate, and long-term maintenance is less certain. (wilson2024bulimianervosaand pages 2-3, donnelly2018neuroimaginginbulimia pages 1-2)

BN carries elevated mortality through suicide and medical complications. A 2024 review cited standardized mortality ratios of approximately 1.5–2.5 and an eightfold greater suicide-death risk than the general population. These are population-level estimates, not individual predictions. (wilson2024bulimianervosaand pages 1-2)

Adverse prognostic features include severe/frequent binge–purge behavior, suicidality, substance use, trauma/PTSD, mood/anxiety comorbidity, medical instability, longer untreated duration, and poor treatment access. A striking 85–94% reportedly delay or never seek treatment, making under-detection a major real-world determinant of outcome. (wilson2024bulimianervosaand pages 1-2)

12. Treatment

Treatment strategy and current implementation

Care should be multidisciplinary and least restrictive while medically safe: medical assessment and stabilization → collaborative nutritional rehabilitation and regular eating → evidence-based psychotherapy → adjunct medication where appropriate → relapse prevention and comorbidity treatment. About 5% of patients were estimated to require inpatient care; dehydration, electrolyte disturbance, arrhythmia, severe self-harm, or psychiatric decompensation are key indications. Partial-hospital programs commonly provide 7–10 hours/day of structured treatment. (alharbi2024effectivetreatmentapproaches pages 5-6)

Psychotherapy. CBT/CBT-E is first-line for adults and targets irregular eating, restraint, binge–purge reinforcement, cognitive distortions, and weight/shape overvaluation. Guided self-help can improve access for less complex cases. Interpersonal therapy is an alternative when CBT is unavailable or unsuitable. DBT-informed approaches may help prominent emotion dysregulation, though they are not generally superior to BN-focused CBT. Suggested MAXO annotations: cognitive behavioral therapy, psychotherapy, nutritional counseling, family therapy, and behavioral intervention. (gkintoni2024clinicalinterventionstrategies pages 30-31, wilson2024bulimianervosaand pages 2-3)

Adolescents. Family-based treatment for BN is strongly supported. One synthesis reported remission of 39% with FBT versus 20% with CBT and 18% with supportive psychotherapy. In an RCT of 109 adolescents aged 12–18, abstinence was 39.4% with FBT-BN versus 19.7% with CBT-A at completion and 44.0% versus 25.4% at 6 months. (alharbi2024effectivetreatmentapproaches pages 5-6)

Pharmacotherapy. Fluoxetine, an SSRI, has the strongest regulatory and trial evidence for adult BN and is usually used at 60 mg/day when appropriate. It may reduce bingeing, vomiting, and depressive symptoms but should generally complement psychotherapy. A 2023 meta-analysis of 33 studies covering 11 drugs found modest effects versus placebo: binge episodes SMD −0.40 (95% CI −0.61 to −0.19), vomiting SMD −0.16 (−0.30 to −0.03), depressive symptoms SMD −0.32 (−0.51 to −0.13), and weight WMD −3.05 kg (−5.97 to −0.13). The evidence included SSRIs, TCAs, MAOIs, topiramate, lithium, and fenfluramine; this does not make all options clinically advisable. (yu2023efficacyofpharmacotherapies pages 1-2)

Bupropion is generally avoided because purging/electrolyte disturbance increases seizure risk. TCAs and MAOIs have greater safety/tolerability burdens. Topiramate has some efficacy but cognitive, metabolic, and teratogenic concerns. No medication is FDA-approved specifically for pediatric BN. No validated genotype-guided therapy, gene/cell/RNA therapy, immunotherapy, or surgery exists. (gkintoni2024clinicalinterventionstrategies pages 30-31)

Experimental/current trials. Retrieved ClinicalTrials.gov records illustrate current directions: MDMA-assisted therapy, NCT07542145, phase 1, recruiting, n=40; group therapy, NCT06063278, completed, n=100; eating-related inhibition/valuation, NCT05995496, recruiting, n=150; smartphone aftercare, NCT05728021, n=172; eating-related neurofeedback, NCT05614024, recruiting, n=30; web intervention, NCT04876196, completed, n=152; neurobiology study, NCT04225221, phase 2, completed, n=10; lisdexamfetamine, NCT03397446, phase 2, terminated, n=23; PET-guided serotonergic treatment, NCT02359513, phase 4, completed, n=51; and rTMS, NCT01530906, status uncertain, n=60. These are investigational and do not establish efficacy.

Access and disparities

The evidence base underrepresents males, older adults, racial/ethnic minorities, and diverse body sizes. Digital CBT, guided self-help, primary-care screening, and stepped care are real-world attempts to close access gaps, but digital delivery still requires suicide and medical-risk pathways. (wilson2024bulimianervosaand pages 1-2, wilson2024bulimianervosaand pages 2-3)

13. Prevention

Primary prevention: school/community programs promoting media literacy, body functionality and diversity, reduced weight stigma, flexible eating, and avoidance of restrictive dieting; safeguards in leanness-focused sports; and trauma-informed environments. No vaccine or prophylactic drug applies.

Secondary prevention: targeted screening in adolescents, athletes, people presenting with dental erosion, recurrent electrolyte disturbance, depression/anxiety, self-harm, or weight-control behaviors; confidential questioning and rapid referral. Because most affected people do not promptly seek care, case finding is a high priority. (wilson2024bulimianervosaand pages 1-2)

Tertiary prevention: relapse plans, continued meal regularity, monitoring for renewed purging, electrolyte/renal/cardiac surveillance when indicated, dental care, suicide prevention, and integrated treatment of mood, anxiety, PTSD, and substance-use disorders. Genetic counseling is not routinely indicated because risk is polygenic and non-deterministic.

14. Other species and natural disease

No well-established naturally occurring animal disease is homologous to human BN, and BN is not infectious, transmissible, or zoonotic. Animals can exhibit binge-like consumption or compensatory restriction, but the human syndrome requires subjective loss of control and weight/shape overvaluation, which cannot be directly established in animals. Therefore, veterinary breed, VBO, natural-disease gene, and cross-species transmission fields should be recorded as not applicable/not established.

15. Model organisms

Rodent binge-eating models use intermittent access to palatable high-fat/high-sugar food, food restriction/refeeding, stress, or limited-access paradigms. They are useful for studying reward, dopamine, serotonin, opioid/endocannabinoid signaling, stress, and candidate drugs. Their central limitation for BN is that rats and mice lack an emetic response; purging must be modeled indirectly through restriction or exercise. They also cannot recapitulate human body-image cognition, shame, or sociocultural influences. Consequently, these are models of components—especially binge behavior—not complete models of BN.

Human fMRI/PET paradigms, ecological momentary assessment, smartphone monitoring, and experimentally controlled meal tasks have higher face validity for cognitive control and cue reactivity. No validated BN organoid, iPSC, humanized genetic model, or single causal-gene knockout exists.

Ontology-ready summary

The following table provides compact knowledge-base annotations. Terms explicitly marked “suggested” require verification against the current ontology release before production ingestion.

Table: This compact table organizes bulimia nervosa into ontology-ready disease, phenotype, anatomy, mechanism, and treatment annotations using only evidence available in the retrieved context. It is useful as a starting point for knowledge-base population, while clearly marking suggested or unverified ontology IDs where the supplied evidence did not provide exact identifiers.

Evidence appraisal and authoritative interpretation

The most reliable current conclusion is that BN is a clinically diagnosed, polygenic and environmentally responsive psychiatric syndrome—not a monogenic, inflammatory, infectious, or biomarker-defined disease. Evidence is strongest for CBT/CBT-E, adolescent FBT, adjunctive fluoxetine, and active medical monitoring. Genetic candidates, microbiome changes, cytokines, neuroimaging, and other omics remain mechanistic research signals rather than clinical tests or treatment-selection biomarkers. (OpenTargets Search: bulimia nervosa, yu2023efficacyofpharmacotherapies pages 1-2, donnelly2018neuroimaginginbulimia pages 1-2, butler2021theroleof pages 10-12, barakat2023riskfactorsfor pages 7-8)

Representative exact abstract language includes: “BN is characterized by recurrent binge eating episodes with inappropriate compensatory behaviors” in the 2023 pharmacotherapy synthesis, and the neuroimaging review concluded that “heterogenous” studies prevented robust conclusions regarding precise neurobiology. The 2024 disparities review’s central real-world warning is that older adults, males, and racial minorities remain systematically underrepresented. (yu2023efficacyofpharmacotherapies pages 1-2, wilson2024bulimianervosaand pages 1-2, donnelly2018neuroimaginginbulimia pages 1-2)

Key recent sources and URLs

• Yu S, et al. Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis. December 2023. https://doi.org/10.1186/s40360-023-00713-7 (yu2023efficacyofpharmacotherapies pages 1-2)
• Wilson K, Kagabo R. Bulimia nervosa and treatment-related disparities: a review. August 2024. https://doi.org/10.3389/fpsyg.2024.1386347 (wilson2024bulimianervosaand pages 1-2, wilson2024bulimianervosaand pages 2-3)
• Gkintoni E, et al. Clinical intervention strategies and family dynamics in adolescent eating disorders. July 2024. https://doi.org/10.3390/jcm13144084 (gkintoni2024clinicalinterventionstrategies pages 30-31)
• Alharbi Y, et al. Effective treatment approaches for eating disorders in children and adolescents. November 2024. https://doi.org/10.7759/cureus.74003 (alharbi2024effectivetreatmentapproaches pages 5-6)
• Barakat S, et al. Risk factors for eating disorders: findings from a rapid review. January 2023. https://doi.org/10.1186/s40337-022-00717-4 (barakat2023riskfactorsfor pages 7-8)
• Donnelly B, et al. Neuroimaging in bulimia nervosa and binge eating disorder: a systematic review. February 2018. https://doi.org/10.1186/s40337-018-0187-1 (donnelly2018neuroimaginginbulimia pages 1-2)
• Butler MJ, et al. The role of the gut microbiome, immunity, and neuroinflammation in the pathophysiology of eating disorders. February 2021. https://doi.org/10.3390/nu13020500 (butler2021theroleof pages 10-12)

PMIDs were not exposed in the retrieved full-text metadata and therefore are not fabricated here; DOI URLs are supplied as stable primary identifiers.

References

1. (yu2023efficacyofpharmacotherapies pages 1-2): Sijie Yu, Yuhan Zhang, Chongkai Shen, and Fei Shao. Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis. BMC Pharmacology and Toxicology, Dec 2023. URL: https://doi.org/10.1186/s40360-023-00713-7, doi:10.1186/s40360-023-00713-7. This article has 23 citations.

2. (wilson2024bulimianervosaand pages 1-2): Kim Wilson and Robert Kagabo. Bulimia nervosa and treatment-related disparities: a review. Frontiers in Psychology, Aug 2024. URL: https://doi.org/10.3389/fpsyg.2024.1386347, doi:10.3389/fpsyg.2024.1386347. This article has 13 citations and is from a peer-reviewed journal.

3. (donnelly2018neuroimaginginbulimia pages 1-2): Brooke Donnelly, Stephen Touyz, Phillipa Hay, Amy Burton, Janice Russell, and Ian Caterson. Neuroimaging in bulimia nervosa and binge eating disorder: a systematic review. Journal of Eating Disorders, Feb 2018. URL: https://doi.org/10.1186/s40337-018-0187-1, doi:10.1186/s40337-018-0187-1. This article has 177 citations and is from a peer-reviewed journal.

4. (barakat2023riskfactorsfor pages 7-8): Sarah Barakat, S. McLean, E. Bryant, Ân H. Lê, P. Marks, Phillip Sarah Robert Leah Emma Susan Belinda Shannon Bronn Aouad Barakat Boakes Brennan Bryant Byrne Caldwell, P. Aouad, Sarah Barakat, R. Boakes, L. Brennan, S. Byrne, Belinda Caldwell, S. Calvert, B. Carroll, D. Castle, I. Caterson, Belinda Chelius, Lyn Chiem, S. Clarke, J. Conti, Lexi Crouch, Genevieve Dammery, Natasha Dzajkovski, J. Fardouly, Carmen Felicia, John Feneley, Amber-Marie Firriolo, N. Foroughi, M. Fuller-Tyszkiewicz, A. Fursland, V. Gonzalez-Arce, Bethanie Gouldthorp, Kelly Griffin, S. Griffiths, A. Hambleton, A. Hannigan, Melissa Hart, S. Hart, P. Hay, I. Hickie, Francis Kay-Lambkin, R. King, M. Kohn, E. Koreshe, I. Krug, Ân H. Lê, Jake Linardon, Randall Long, Amanda Long, S. Madden, S. Maguire, D. Maloney, S. McLean, Thy Meddick, J. Miskovic-Wheatley, Deborah Mitchison, R. O’Kearney, S. Ong, R. Paterson, S. Paxton, Melissa J Pehlivan, G. Pépin, A. Phillipou, J. Piccone, R. Pinkus, Bronwyn C Raykos, P. Rhodes, E. Rieger, Sarah Rodan, Karen Rockett, J. Russell, H. Russell, Fiona Salter, Susan S. Sawyer, Beth. Shelton, Urvashnee Singh, Sophie Smith, Evelyn Smith, K. Spielman, S. Squire, J. Thomson, M. Tiggemann, S. Touyz, Ranjani Utpala, L. Vartanian, Andrew Wallis, W. Ward, Sarah Wells, E. Wertheim, S. Wilksch, and Michelle Williams. Risk factors for eating disorders: findings from a rapid review. Journal of Eating Disorders, Jan 2023. URL: https://doi.org/10.1186/s40337-022-00717-4, doi:10.1186/s40337-022-00717-4. This article has 580 citations and is from a peer-reviewed journal.

5. (gkintoni2024clinicalinterventionstrategies pages 30-31): Evgenia Gkintoni, Elias Kourkoutas, Stephanos P. Vassilopoulos, and Maria Mousi. Clinical intervention strategies and family dynamics in adolescent eating disorders: a scoping review for enhancing early detection and outcomes. Jul 2024. URL: https://doi.org/10.3390/jcm13144084, doi:10.3390/jcm13144084. This article has 45 citations.

6. (alharbi2024effectivetreatmentapproaches pages 5-6): Yara Alharbi, Fatema Saleh, and Khaled A Shahat. Effective treatment approaches for eating disorders in children and adolescents: a review article. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.74003, doi:10.7759/cureus.74003. This article has 7 citations.

7. (OpenTargets Search: bulimia nervosa): Open Targets Query (bulimia nervosa, 0 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (wilson2024bulimianervosaand pages 2-3): Kim Wilson and Robert Kagabo. Bulimia nervosa and treatment-related disparities: a review. Frontiers in Psychology, Aug 2024. URL: https://doi.org/10.3389/fpsyg.2024.1386347, doi:10.3389/fpsyg.2024.1386347. This article has 13 citations and is from a peer-reviewed journal.

9. (butler2021theroleof pages 10-12): Michael J. Butler, Alexis A. Perrini, and Lisa A. Eckel. The role of the gut microbiome, immunity, and neuroinflammation in the pathophysiology of eating disorders. Nutrients, 13:500, Feb 2021. URL: https://doi.org/10.3390/nu13020500, doi:10.3390/nu13020500. This article has 109 citations.

Artifacts

• Edison artifact artifact-00